BETWEENLease Agreement • February 6th, 2004 • Barrier Therapeutics Inc • New Jersey
EXHIBIT 10.4Employment Agreement • April 2nd, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
EXHIBIT 1.1 5,000,000 SHARES BARRIER THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT Morgan Stanley & Co. Incorporated Banc of America Securities LLC J.P. Morgan Securities Inc. c/o Morgan Stanley & Co. Incorporated...Underwriting Agreement • April 2nd, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
EXHIBIT 1 to Schedule 13G JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this...Joint Filing Agreement • February 14th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations
BACKGROUNDLease Agreement • August 11th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations
EXHIBIT 1.1 4,000,000 SHARES BARRIER THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT FEBRUARY ___, 2005Barrier Therapeutics Inc • February 1st, 2005 • Pharmaceutical preparations • New York
EXHIBIT 10.25 Confidential Execution Copy FINISHED PRODUCT SUPPLY AGREEMENT executed as of the date last below written (hereinafter referred to as "Effective Date") by and between JANSSEN PHARMACEUTICA, Naamloze Vennootschap, a business corporation...Supply Agreement • February 1st, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations
RECITALSRights Agreement • February 6th, 2004 • Barrier Therapeutics Inc • Delaware
AMENDMENT NO. 1 TO THE RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • April 28th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
EXHIBIT 4.2 BARRIER THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • January 24th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations • Delaware
Exhibit 10.15 **Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. DEVELOPMENT AND SUPPLY AGREEMENT THIS AGREEMENT (hereinafter...Development and Supply Agreement • April 28th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations
LOAN1000* MASTER SECURITY AGREEMENT dated as of August 20, 2003 (" Agreement") THIS AGREEMENT is between General Electric Capital Corporation (together with its successors and assigns, if any, "Secured Party") and Barrier Therapeutics, Inc....Master Security Agreement • February 6th, 2004 • Barrier Therapeutics Inc
EXHIBIT 10.7 BARRIER HEALTH TECHNOLOGIES INC. RESTRICTED STOCK PURCHASE AGREEMENT THIS AGREEMENT is made as of October 31, 2001 by and between BARRIER HEALTH TECHNOLOGIES INC., a Delaware corporation (the "Company") and Dr. Geert Cauwenbergh (the...Restricted Stock Purchase Agreement • April 2nd, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
BY AND AMONGDistribution and License Agreement • November 9th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations
AGREEMENT AND PLAN OF MERGER by and among STIEFEL LABORATORIES, INC., BENGAL ACQUISITION INC. and BARRIER THERAPEUTICS, INC. Dated as of June 23, 2008Agreement and Plan of Merger • June 24th, 2008 • Barrier Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (hereinafter referred to as this “Agreement”) is entered into as of June 23, 2008, by and among Stiefel Laboratories, Inc. (“Parent”), a Delaware corporation, Bengal Acquisition Inc. (“Purchaser”), a Delaware corporation and direct wholly-owned subsidiary of Parent, and Barrier Therapeutics, Inc., a Delaware corporation (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 17th, 2008 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into this 14th day of March, 2008, to be effective as of May 1, 2008 (the “Effective Date”) by and between Barrier Therapeutics, Inc., a Delaware corporation having its principal offices in Princeton, New Jersey (the “Company”), and Dennis P. Reilly (the “Executive”).
CREDIT AND SECURITY AGREEMENTCredit and Security Agreement • August 8th, 2007 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
THIS CREDIT AND SECURITY AGREEMENT (as the same may be amended, supplemented, restated or otherwise modified from time to time, the “Agreement”) is dated as of June 29, 2007 by and among (a) BARRIER THERAPEUTICS, INC., a Delaware corporation, and any additional Borrower that may hereafter be added to this Agreement (each individually as a “Borrower”, and collectively as “Borrowers”), (b) MERRILL LYNCH CAPITAL, a division of Merrill Lynch Business Financial Services Inc., individually as a Lender, and as Administrative Agent, and (c) the financial institutions or other entities from time to time parties hereto, each as a Lender.
BY AND BETWEENProduct Acquisition Agreement • February 7th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • September 24th, 2007 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
EXHIBIT 10.2 INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENT This Intellectual Property Transfer and License Agreement (this "Agreement") is made by and between Johnson & Johnson Consumer Companies, Inc., a New Jersey corporation having an...Transfer and License Agreement • April 28th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
4,820,000 Shares of Common Stock Barrier Therapeutics, Inc. (a Delaware corporation) Common Stock Underwriting AgreementBarrier Therapeutics Inc • September 15th, 2006 • Pharmaceutical preparations • Delaware
Barrier Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the Underwriters named in Schedule I annexed hereto (the “Underwriters”) an aggregate of 4,820,000 shares of Common Stock, $0.0001 par value per share (the “Common Stock”), of the Company (the “Firm Shares”). The Firm Shares are also referred to as the “Offered Securities.”
AMENDMENT NO. 1 TO THE RESTRICTED STOCK PURCHASE AGREEMENTRestricted Stock Purchase Agreement • April 2nd, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
EMPLOYMENT AGREEMENTEmployment Agreement • March 25th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated as of the 1st day of April, 2004, is between Barrier Therapeutics, Inc., a Delaware corporation (the “Corporation”) and Albert C. Bristow (the “Executive”).
BARRIER THERAPEUTICS, INC. SCIENCE ADVISORY BOARD CONSULTING AGREEMENTScience Advisory Board Consulting Agreement • August 12th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
This SCIENCE ADVISORY BOARD CONSULTING AGREEMENT (this “Agreement”) dated as of August 1, 2005 (the “Effective Date”), is entered into by and between Barrier Therapeutics, Inc., a Delaware corporation, having a principal place of business at 600 College Road East, Suite 3200, Princeton, New Jersey, 08540 (the “Company”), and Carl Ehmann, an individual with a principal address at 134 Broad Street, Charleston, South Carolina 29401 (the “Advisor”).
ContractBarrier Therapeutics Inc • March 12th, 2008 • Pharmaceutical preparations
Confidential Treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “***”. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
SUPPLY AGREEMENTSupply Agreement • August 8th, 2007 • Barrier Therapeutics Inc • Pharmaceutical preparations
THIS SUPPLY AGREEMENT (hereinafter “Supply Agreement”) is made this 12 day of July, 2007 (the “Effective Date”) by and between Abbott GmbH & Co. KG, having a place of business at Max-Planck Ring 2, 65205 Wiesbaden, Germany and a facility at Knollstrasse 50, 67061 Ludwigshafen, Germany (hereinafter “Abbott”), and Barrier Therapeutics, Inc., having a place of business at Suite 3200, 600 College Road East, Princeton NJ 08540, USA (hereinafter “Barrier”).
SALES FORCE SERVICES AGREEMENTSales Force Services Agreement • March 12th, 2007 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
This Sales Force Services Agreement (this “Agreement”), with an Effective Date of March 2, 2007, sets forth the terms and conditions between Novartis Consumer Health, Inc., 200 Kimball Drive, Parsippany, N.J. 07054 (hereafter “Novartis”), and Barrier Therapeutics, Inc., 600 College Road East, Princeton, NJ 08540 (hereinafter “Barrier”).
AMENDMENT NO. 1 TO JJCC INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENTIntellectual Property Transfer and License Agreement • September 10th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 1 (the “JJCC Amendment”) is made and entered into as of September 7, 2004 by and between Johnson & Johnson Consumer Companies, Inc., a New Jersey corporation having an address at 199 Grandview Road, Skillman, New Jersey 08558 (hereinafter referred to as “JJCC”) and Barrier Therapeutics, Inc., a Delaware corporation having an address at 600 College Road East, Suite 3200, Princeton, New Jersey 08540 (hereinafter referred to as “Barrier”).
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASEConfidential Separation Agreement and General Release • April 2nd, 2008 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
THIS CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (this “Severance Agreement”) is made and entered into effective as of this 31st day of March, 2008, by and between Barrier Therapeutics, a Delaware corporation (the “Company”) and Geert Cauwenbergh, Ph.D. (“Cauwenbergh”) (collectively, “the parties”).
AMENDMENT TO THE FINISHED PRODUCT SUPPLY AGREEMENTThe Finished Product Supply Agreement • November 14th, 2005 • Barrier Therapeutics Inc • Pharmaceutical preparations
This Amendment (the “Amendment”) is made and entered into as of August 26, 2005 by and between Janssen Pharmaceutica, NV, a business corporation organized under the Laws of Belgium, having its principal office at B-2340 Beerse, Turnhoutseweg 30, Belgium (hereinafter referred to as “Janssen”) and Barrier Therapeutics, Inc., a Delaware corporation having an address at 600 College Road East, Suite 3200, Princeton, New Jersey 08540 (hereinafter referred to as “Barrier”).
Re: Amendment No. 1 (this “Amendment”) to the Pharmaceutical Product Supply Agreement dated January 27, 2005 (the “Agreement”) by and between DSM Pharmaceuticals, Inc. (“DSM”) and Barrier Therapeutics, Inc. (“Barrier”)Barrier Therapeutics Inc • March 12th, 2007 • Pharmaceutical preparations
This letter confirms the recent discussions between DSM and Barrier regarding the proposed amendment of the Pharmaceutical Product Supply Agreement (the “Agreement”) referenced above. All terms and conditions defined herein are used as defined in the Agreement.
AMENDMENT NO. 1 TO JPPLP INTELLECTUAL PROPERTY TRANSFER AND LICENSE AGREEMENTTransfer and License Agreement • September 10th, 2004 • Barrier Therapeutics Inc • Pharmaceutical preparations • New York
This Amendment No. 1 (the “JPPLP Amendment”) is made and entered into as of September 7, 2004 by and between Janssen Pharmaceutica Products, L.P., a New Jersey limited partnership having a principal place of business at 1123 Trenton-Harbourton Road, Titusville, New Jersey 08628 (hereinafter referred to as “JPPLP”) and Barrier Therapeutics, Inc., a Delaware corporation having an address at 600 College Road East, Suite 3200, Princeton, New Jersey 08540 (hereinafter referred to as “Barrier”).
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASEConfidential Separation Agreement and General Release • May 1st, 2008 • Barrier Therapeutics Inc • Pharmaceutical preparations • New Jersey
THIS CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (this “Severance Agreement”) is made and entered into effective as of this 30th day of April, 2008, by and between Barrier Therapeutics, a Delaware corporation (the “Company”) and Anne VanLent (“VanLent”) (collectively, “the parties”).
PHARMACEUTICAL PRODUCT SUPPLY AGREEMENT Dated January 27, 2005 By and Between DSM PHARMACEUTICALS, INC. and BARRIER THERAPEUTICS, INC.Quality Agreement • March 12th, 2007 • Barrier Therapeutics Inc • Pharmaceutical preparations • North Carolina
September 21, 2007 Anne VanLent Executive Vice President, Chief Financial Officer Barrier Therapeutics, Inc. Princeton, NJ 08540-6697 Dear Anne:Confirm the Agreement • September 24th, 2007 • Barrier Therapeutics Inc • Pharmaceutical preparations • California
This is to confirm the agreement (this “Agreement”) between Pacific Growth Equities, LLC (“PGE” or “Pacific Growth”) and Barrier Therapeutics, Inc. (the “Company”) as follows:
